WHO to review MSD’s Ebola vaccine for emergency use
December 24, 2015Manufacturing and Production, Research and Development Ebola vaccine, Ebola virus, MSD, WHO, Zebov
The World Health Organisation (WHO) has accepted MSD’s application for the company’s investigational Ebola vaccine, V920 (Zebov), to be reviewed …
J&J and Purdue settle Kentucky lawsuits for $39.5 million
December 24, 2015Sales and Marketing Johnson and Johnson, Kentucky, OxyContin, Purdue Pharma, Risperdal, lawsuits
Johnson & Johnson and Purdue Pharma have settled separate lawsuits with the US state of Kentucky for a total of …
Boehringer Ingelheim invests in Europe
December 24, 2015Manufacturing and Production, Sales and Marketing Austria, Biberach, Boehringer Ingelheim, Vienna, biologicals, manufacturing, production
Boehringer Ingelheim will kick off its pharma investments in 2016 with a half a billion Euro outlay and plans to …
OTC drugs market boosted by growing patient demand
December 24, 2015Manufacturing and Production, Sales and Marketing GBI Research, OTC, generics, over the counter
Increasing pressures from customers, drug manufacturers and regulators to convert prescription medications to over-the-counter (OTC) non-prescription status is driving growth …
Seven pharma trends for 2016
December 24, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing
What will be the key industry trends in 2016?Pricing pressures
Celgene settles Revlimid patent dispute
December 23, 2015Manufacturing and Production, Research and Development, Sales and Marketing Celgene, India, Natco, Revlimid, lenalidomide, patents
Celgene has settled its litigation with Natco Pharma, over the patents for Revlimid, opening the door to increased generic competition …
FDA approves AstraZeneca’s gout drug Zurampic
December 23, 2015Sales and Marketing AstraZeneca, FDA, Zurampic, gout, lensinurad
The US FDA has approved AstraZeneca’s Zurampic to treat high levels of uric acid in the blood. The drug is …
NICE recommends Velcade for MCL, and three diabetes drugs
December 23, 2015Sales and Marketing Forxiga, NICE, Velcade, invokana, jardiance, mantel cell lymphoma, mcl
NICE has published final guidance recommending Velcade (bortezomib) as a treatment for previously untreated mantle cell lymphoma (MCL). In the …
100 year old chemical could be the future of cancer treatment
December 23, 2015Research and Development Cancer, PV-10, Peter Culpepper, Provectus, Rose Bengal, oncology
Peter Culpepper, chief operating officer at Provectus Biopharmaceuticals, explains the secrets of Rose Bengal, which has impressed in clinical trials …
Researchers question price of GSK’s Nucala
December 23, 2015Research and Development GSK, HEOR, ICER, Nucala, asthma, cost-effective, health economics, health economics outcomes research
GSK is charging up to four times more for its recently approved asthma drug Nucala than is justified by cost-effectiveness …
Janssen and Bavarian Nordic to collaborate on HPV vaccine
December 23, 2015Research and Development Bavarian Nordic, HPV, Janssen, Vaccine, human papillomavirus, prime boost
Janssen has announced a new collaboration and license agreement with Bavarian Nordic to develop a vaccine for chronic Human Papillomavirus …
Merck and Pfizer kick off Phase III avelumab cancer trials
December 23, 2015Research and Development Merck, Pfizer, avelumab, ovarian cancer
Merck and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients …
Actelion ready to launch Uptravi after FDA approval
December 22, 2015Research and Development, Sales and Marketing Actelion, FDA, Jean-Paul Clozel, Uptravi, pulmonary arterial hypertension, selexipag
Actelion says it is ready to launch Uptravi, its drug for pulmonary arterial hypertension in the US in January, after …
Shire moves to seal Baxalta deal with improved offer
December 22, 2015Research and Development, Sales and Marketing Baxalta, Flemming Ornskov, Shire
Shire is set to sweeten its $30 billion bid for Baxalta by offering 40% of the total, or $12 billion, …
EMA adds warning label to Novartis’ MS treatment Gilenya
December 22, 2015Manufacturing and Production EMA, European Medicines Agency, FDA, Novartis, PML, basal cell carcinoma, fingolimod, gilenya
Drug safety regulators in Europe have said they will add warnings to the label and prescribing information of Gilenya (fingolimod), …
Pharma industry will pay £550m of NHS 2016 drugs bill
December 22, 2015Manufacturing and Production ABPI, PPRS, Pharmaceutical Price Regulation Scheme
A new financial agreement announced this week as part of the Pharmaceutical Price Regulation Scheme (PPRS), will see the pharmaceutical …
Sun Pharma hit by FDA inspection warning
December 22, 2015Manufacturing and Production FDA, Sun Pharma, manufacturing, production
Sun Pharma shares fell some 7% early this week after it emerged the Indian company received a warning letter from …
Former Cubist chief executive Michael Bonney to chair board at Alnylam
December 22, 2015Manufacturing and Production, Research and Development, Sales and Marketing Alnylam, David Pyott, michael bonney
Michael Bonney, current board member and former chief executive of Cubist Pharmaceuticals, has been appointed as chairman of Alnylam Pharmaceuticals …
Two billion people still lack medicines access. Is the industry doing enough?
December 22, 2015Manufacturing and Production Access to Medicine Foundation, Access to Medicine Index, affordability, market access, medicines access, pricing
“We have a mission to encourage the pharmaceutical industry in improving access to medicine for the two billion people who …
EMA management board chair stands down
December 21, 2015Manufacturing and Production, Sales and Marketing EMA, European Medicines Agency, Sir Kent Woods
Sir Kent Woods will step down as chair of the board at the EMA from the end of December 2015. …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
